首页/数据集/Additional file 3 of Allergen fragrance molecules: a potential relief for COVID-19

Additional file 3 of Allergen fragrance molecules: a potential relief for COVID-19

Name: Additional file 3 of Allergen fragrance molecules: a potential relief for COVID-19
Creator: Aslı Deniz Aydın
Published: 2021-01-23T00:00:00+08:00

Figshare2021-01-23 更新2026-04-08 收录

过敏原毒理学

药物安全性评估

数据链接：

https://springernature.figshare.com/articles/dataset/Additional_file_3_of_Allergen_fragrance_molecules_a_potential_relief_for_COVID-19/13627135/1 数据链接链接失效反馈

官方服务：

资源简介：

Additional file 3. PASSonline Toxicology results: allergen toxicology data.

应用场景：

提供机构：

Aslı Deniz Aydın

创建时间：

2021-01-23

药物不良反应监测

药物安全性评估

This study analyzed adverse drug event (ADE) signals associated with metreleptin using the FDA Adverse Event Reporting System (FAERS) to provide insights for safe clinical use. Data from 1 January 201

DataCite Commons2026-05-04 更新120

Rates of systemic adverse effects of head-to-head studies (direct comparison).

药物安全性评估

癌症治疗不良反应

Nr: Not reported. *Data from CATT appendix: they refer to duodenal ulcer haemorrhage, gastric ulcer haemorrhage, (lower) gastrointestinal haemorrhage, rectal haemorrhage. #Rates refer mainly to pneumo

NIAID Data Ecosystem60

Efficacy, safety, and ARIA risk of anti–β-amyloid antibodies in early Alzheimer’s disease: a systematic review, meta-analysis, and meta-regression

阿尔茨海默病药物

药物安全性评估

Alzheimer’s disease (AD) is the most prevalent cause of dementia and has been closely linked to βSupplemental data for this article can be accessed online at ht tps://doi.org/-amyloid accumulation. Ho

NIAID Data Ecosystem40

A Phase 2 Randomized Trial of Apremilast in Patients With Atopic Dermatitis. A Phase 2 Randomized Trial of Apremilast in Patients With Atopic Dermatitis

特应性皮炎

药物安全性评估

A phase 2, double-blind, placebo-controlled trial evaluated apremilast efficacy, safety, and pharmacodynamics in adults with moderate to severe atopic dermatitis (AD). Overall design: Patients were ra

NIAID Data Ecosystem100

Prior and Concomitant Medications and Systemic Antimicrobials in Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants <750 Grams Birth Weight

新生儿抗真菌预防

药物安全性评估

Prior and Concomitant Medications and Systemic Antimicrobials Dataset Study Description This was a prospective, randomized, double-blind, multi-center, efficacy study comparing fluconazole prophylaxis

NIAID Data Ecosystem50

Additional file 3 of Allergen fragrance molecules: a potential relief for COVID-19

资源简介：

相关数据集